Contact this trialFirst, we need to learn more about you.
Cholinergic Agonist
KarXT for Schizophrenia
Recruiting2 awardsPhase 3
Media, Pennsylvania
This trial is testing the long-term safety and efficacy of a new drug, KarXT, for people with schizophrenia. The drug is a combination of xanomeline and trospium chloride, and will be taken twice daily for up to 52 weeks. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with a DSM-5 diagnosis of schizophrenia. The secondary objective of this study is to assess the long-term efficacy and characterize the pharmacokinetics of xanomeline and trospium after administration of KarXT.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.